STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
18.35
-0.11 (-0.60%)
Mar 9, 2026, 3:38 PM EDT - Market open
STAAR Surgical Company Revenue
In the fiscal year ending January 2, 2026, STAAR Surgical Company had annual revenue of $239.44M, down -23.72%. STAAR Surgical Company had revenue of $57.80M in the quarter ending January 2, 2026, with 18.08% growth.
Revenue (ttm)
$239.44M
Revenue Growth
-23.72%
P/S Ratio
3.76
Revenue / Employee
$206,951
Employees
1,157
Market Cap
908.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 2, 2026 | 239.44M | -74.46M | -23.72% |
| Dec 27, 2024 | 313.90M | -8.51M | -2.64% |
| Dec 29, 2023 | 322.42M | 38.02M | 13.37% |
| Dec 30, 2022 | 284.39M | 53.92M | 23.40% |
| Dec 31, 2021 | 230.47M | 67.01M | 41.00% |
| Jan 1, 2021 | Pro | Pro | Pro |
| Jan 3, 2020 | Pro | Pro | Pro |
| Dec 28, 2018 | Pro | Pro | Pro |
| Dec 29, 2017 | Pro | Pro | Pro |
| Dec 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| Embecta | 1.08B |
| Azenta | 595.03M |
| AtriCure | 534.53M |
| AngioDynamics | 307.31M |
| LeMaitre Vascular | 249.60M |
| BioLife Solutions | 96.21M |
| Kestra Medical Technologies | 74.26M |
STAA News
- 5 days ago - STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - STAAR Surgical Issues Shareholder Letter - Business Wire
- 5 days ago - STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results - Business Wire
- 11 days ago - STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction - Business Wire
- 13 days ago - STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026 - Business Wire
- 19 days ago - FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction - Business Wire
- 5 weeks ago - STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs - Business Wire
- 7 weeks ago - STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence - Benzinga